Zealand Pharma A/S
CSE:ZEAL

Watchlist Manager
Zealand Pharma A/S Logo
Zealand Pharma A/S
CSE:ZEAL
Watchlist
Price: 485.7 DKK 4.12% Market Closed
Market Cap: 34.5B DKK

Relative Value

The Relative Value of one ZEAL stock under the Base Case scenario is 101.66 DKK. Compared to the current market price of 485.7 DKK, Zealand Pharma A/S is Overvalued by 79%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ZEAL Relative Value
Base Case
101.66 DKK
Overvaluation 79%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
9
vs Industry
5
Median 3Y
114
Median 5Y
74.1
Industry
6.9
Forward
8.3
vs History
vs Industry
Median 3Y
-22.8
Median 5Y
-12.9
Industry
22.4
Forward
71.9
vs History
vs Industry
Median 3Y
-23.5
Median 5Y
-14.2
Industry
19.1
vs History
vs Industry
Median 3Y
-13.1
Median 5Y
-11.4
Industry
23.2
vs History
95
vs Industry
20
Median 3Y
9.6
Median 5Y
6.8
Industry
2.5
vs History
9
vs Industry
5
Median 3Y
105.7
Median 5Y
73.2
Industry
7.5
Forward
6.4
vs History
9
vs Industry
3
Median 3Y
88.5
Median 5Y
58.8
Industry
8.9
vs History
vs Industry
Median 3Y
-20.3
Median 5Y
-13.6
Industry
4
Forward
357.8
vs History
vs Industry
Median 3Y
-19.9
Median 5Y
-12.7
Industry
3.7
Forward
14.6
vs History
vs Industry
Median 3Y
-21.6
Median 5Y
-12.2
Industry
4.5
vs History
vs Industry
Median 3Y
-21
Median 5Y
-11.4
Industry
3.4
vs History
47
vs Industry
8
Median 3Y
52.2
Median 5Y
24.7
Industry
4.6

Multiples Across Competitors

ZEAL Competitors Multiples
Zealand Pharma A/S Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
Zealand Pharma A/S
CSE:ZEAL
34.3B DKK 547.4 -31.8 -21.3 -20.9
FR
Pharnext SCA
OTC:PNEXF
6T USD 35 123 260.7 -166 935.6 -202 713.1 -200 399.9
US
Abbvie Inc
NYSE:ABBV
350.4B USD 6.2 82.7 16.3 24.6
US
Amgen Inc
NASDAQ:AMGN
151B USD 4.5 36.9 15.2 26.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
128.8B USD 11.7 -240.4 26.3 27.6
US
Gilead Sciences Inc
NASDAQ:GILD
129.2B USD 4.5 269.1 10.6 13.3
US
Epizyme Inc
F:EPE
94.1B EUR 2 005.8 -511.8 -557.3 -542.5
AU
CSL Ltd
ASX:CSL
124.2B AUD 5.3 29.1 17.9 22.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
66.4B USD 4.7 15 9.5 10.6
US
Seagen Inc
F:SGT
39.3B EUR 19.3 -59.2 -63.8 -57.6
NL
argenx SE
XBRU:ARGX
34.6B EUR 17.9 47 -2 655.9 -1 780.7
P/S Multiple
Revenue Growth P/S to Growth
DK
Zealand Pharma A/S
CSE:ZEAL
Average P/S: 3 193 262.5
547.4
204%
2.7
FR
Pharnext SCA
OTC:PNEXF
35 123 260.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.2
7%
0.9
US
Amgen Inc
NASDAQ:AMGN
4.5
4%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.7
10%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.5
3%
1.5
US
E
Epizyme Inc
F:EPE
2 005.8
N/A N/A
AU
CSL Ltd
ASX:CSL
5.3
7%
0.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.7
6%
0.8
US
S
Seagen Inc
F:SGT
19.3
30%
0.6
NL
argenx SE
XBRU:ARGX
17.9
39%
0.5
P/E Multiple
Earnings Growth PEG
DK
Zealand Pharma A/S
CSE:ZEAL
Average P/E: 80
Negative Multiple: -31.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -166 935.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
82.7
87%
1
US
Amgen Inc
NASDAQ:AMGN
36.9
44%
0.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -240.4 N/A N/A
US
Gilead Sciences Inc
NASDAQ:GILD
269.1
187%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -511.8 N/A N/A
AU
CSL Ltd
ASX:CSL
29.1
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15
10%
1.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.2 N/A N/A
NL
argenx SE
XBRU:ARGX
47
28%
1.7
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
Zealand Pharma A/S
CSE:ZEAL
Average EV/EBITDA: 16
Negative Multiple: -21.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -202 713.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
15.2
17%
0.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.3
18%
1.5
US
Gilead Sciences Inc
NASDAQ:GILD
10.6
7%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -557.3 N/A N/A
AU
CSL Ltd
ASX:CSL
17.9
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
9.5
14%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -63.8 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 655.9 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
Zealand Pharma A/S
CSE:ZEAL
Average EV/EBIT: 20.9
Negative Multiple: -20.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -200 399.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
24.6
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
26.9
31%
0.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.6
17%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
13.3
11%
1.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -542.5 N/A N/A
AU
CSL Ltd
ASX:CSL
22.4
14%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.6
13%
0.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.6 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -1 780.7 N/A N/A